Accelerated Communication Endoxifen , the Active Metabolite of Tamoxifen , Is a Substrate of the Efflux Transporter P-Glycoprotein ( Multidrug Resistance 1 )

Tamoxifen is widely prescribed to patients with estrogen receptor-positive breast cancer, and it is a prodrug that requires bioactivation by cytochrome P450 enzymes CYP2D6 and 3A4 to generate the active metabolite, endoxifen. Large interpatient variability in endoxifen plasma levels has been reported, and polymorphisms in CYP2D6 have been implicated as a… CONTINUE READING